Market open

Y-mAbs/$YMAB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Y-mAbs

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Ticker

$YMAB
Trading on

Industry

Biotechnology

Employees

100

Y-mAbs Metrics

BasicAdvanced
$452M
Market cap
-
P/E ratio
-$0.54
EPS
0.67
Beta
-
Dividend rate
$452M
0.67
$20.90
$5.29
244K
3.917
3.481
0.323
1.163
-11.98%
-24.78%
5.258
4.89
5.02
-20.318
-8.99%
22.75%
22.45%
-15.66%

What the Analysts think about Y-mAbs

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Y-mAbs stock.

Y-mAbs Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Y-mAbs Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $YMAB

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Y-mAbs stock?

Y-mAbs (YMAB) has a market cap of $452M as of November 22, 2024.

What is the P/E ratio for Y-mAbs stock?

The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of November 22, 2024.

Does Y-mAbs stock pay dividends?

No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Y-mAbs dividend payment date?

Y-mAbs (YMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Y-mAbs?

Y-mAbs (YMAB) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.